二甲双胍用于2型糖尿病患者的肝癌预防:一项系统综述和Meta分析

Metformin for liver cancer prevention in patients with type 2 diabetes: A systematic review and meta-analysis
2012-07-25 10:49点击:236次发表评论
作者:Zhang, Z.-J.a , Zheng, Z.-J.a, Shi, R.b, Su, Q.c,
机构: 上海交通大学公共卫生学院流行病与卫生统计学系
期刊: J CLIN ENDOCR METAB2012年7月7期97卷

Department of Epidemiology and Biostatistics, School of Public Health, Shanghai Jiao Tong University, Shanghai 200025, China

Context: Data on the potential effect of metformin on the risk of liver cancer are limited and inconsistent. Objective: The objective of this study was to review the evidence currently available to examine the potential role of metformin in chemoprevention for liver cancer in patients with type 2 diabetes. Data Sources: The data sources of the study included the PubMed and SciVerse Scopus databases. Study Selection: Selection included studies that assessed the effect of metformin therapy on the risk of liver cancer in patients with type 2 diabetes. Data Extraction: Summary effect estimates were derived using a random-effects meta-analysis model. Data Synthesis: A database was developed on the basis of five studies consisting of approximately 105,495 patients with type 2 diabetes. In meta-analyses, metformin was associated with an estimated 62% reduction in the risk of liver cancer among patients with type 2 diabetes (odds ratio 0.38, 95% confidence interval 0.24, 0.59; P < 0.001). The effect estimates were heterogeneous across the five included studies (P for heterogeneity = 0.001; I 2 = 78%). When restricting the analysis to the four studies related to hepatocellular carcinoma, metformin was again associated with a significantly lower cancer risk (odds ratio 0.30, 95% confidence interval 0.17, 0.52; P < 0.001), and there was evidence of significant heterogeneity between these four studies (P for heterogeneity = 0.03; I 2 = 67%). Conclusions: Metformin appears to be associated with a lower risk of liver cancer in patients with type 2 diabetes. Further investigation, including mechanistic studies, well-designed cohort studies, and possibly controlled trials, is needed. Copyright © 2012 by The Endocrine Society.

Zhang, Z.-J.; Department of Epidemiology and Biostatistics, School of Public Health, Shanghai Jiao Tong University, Shanghai 200025, China; email: zhang.zj@msn.com

通讯作者:Zhang, Z.-J.; Department of Epidemiology and Biostatistics, School of Public Health, Shanghai Jiao Tong University, Shanghai 200025, China; email: zhang.zj@msn.com
学科代码:内分泌学与糖尿病   关键词:二甲双胍用于2型糖尿病患者的肝癌预防:一项系统综述和Meta
来源: Scopus
Scopus介绍:Scopus 于2004年11月正式推出,是目前全球规模最大的文摘和引文数据库。Scopus涵盖了由5000多家出版商出版发行的科技、医学和社会科学方面的18,000多种期刊,其中同行评审期刊16,500多种。相对于其他单一的文摘索引数据库而言,Scopus的内容更加全面,学科更加广泛,特别是在获取欧洲及亚太地区的文献方面,用户可检索出更多的文献数量。通过Scopus,用户可以检索到1823年以来的近4000万条摘要和题录信息,以及1996年以来所引用的参考文献。数据每日更新。 马上访问Scopus网站http://www.scopus.com/
顶一下(0
您可能感兴趣的文章
    发表评论网友评论(0)
      发表评论
      登录后方可发表评论,点击此处登录